Scientific & Technical Instruments. Scored on the same transparent model behind the daily rankings.
★
MKSI
MKS Inc. · Scientific & Technical Instruments
54.8Score
$264.50Oct 9 close$17.9B
1Y Target$410.86Analyst consensus · 14 analysts
5Y Target$601.54Compound horizon
10Y Target$892.34Long-dated conviction
FCF$455mTTM · 06/26C
FCF $455m — modest; watch for margin expansion · TTM from SEC filings (OCF − CapEx), four quarters to 06/26.
Rev+16.3%TTM YoYB+
Revenue +16.3% — above sector median, healthy trajectory · Latest four quarters of revenue vs the four before them, from SEC filings.
D/E1.40C
D/E 1.40 — more levered than most Technology peers (≈90th pctile)
P/E41.4xC+
P/E 41.4 — above the Technology median (≈75th pctile)
PEG1.32B
PEG 1.32 — acceptable premium for growth
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 54.8
Quality52.7
Growth86.8
Value35.9
Why this score
Raising its dividend
Entry · Margin of safety
52-week rangeMid-range
41% off the 12-month high
vs DCF fair value228% aboveest. fair value ~$81
What the price assumes: free cash flow growing about 45% next year, slowing to 4% a year by year ten — vs a starting rate of ~16% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Quality signals
Gross profitability25% · Bgross profit ÷ total assets — not in the score
ROIC6.8% · C+return on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Scientific & Technical Instruments · market cap $17.9b. Down 41% from 52-week high of $447.62 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 14 sell-side analysts publish a mean 1-yr target of $410.86 (implying +55% upside).
Moat
ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 103% of net income — earnings translate cleanly into cash.
Risk
Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.02 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon
1-3 yr $410.86 (14-analyst consensus) — fundamentals + valuation re-rating. 5 yr $601.54 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $892.34 if current growth sustains into durable earnings power.
MKSI vs the Top Picks average
Pillar
MKSI
Book avg
Diff
Quality
53
83
-30
Growth
87
89
-2
Value
36
76
-40
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · MKSI
Trend
+9.6 over 82 daily scores
From 45.2 (Jun 22) → 54.8 (now)
One point per daily run; read From → To for the actual range.
MKSI at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
-0.3%
90-day change
+15.3%
Forward EPS estimate
$17.55
Over the last 90 days, what analysts expect MKSI to earn is materially higher (+15.3%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · MKSI
$
%
%
Shares to buy
7
Position size
$1,852
3.7% of portfolio
Stop price
$198.38
25% below $264.50
$ at risk if stopped
$462.88
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
MKS Inc. (MKSI): score, valuation & FAQ
MKS Inc. (MKSI) is a Scientific & Technical Instruments company that scores 54.8 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (B+). On valuation, MKSI sits about 228% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 45% next year, slowing to 4% a year by year ten.
Is MKSI a good stock to buy?
Bull Rankings scores MKSI 54.8 out of 100 on its quality-growth model, which is a middling reading. That is driven by Rev (B+). A score is a quantitative screen of MKS Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does MKSI score 54.8 on Bull Rankings?
The score leans on growth at 86.8 out of 100, with value the weakest pillar at 35.9 — the three combine geometrically, so a weak one cannot be papered over by a strong one. MKSI earns its highest marks on Rev (B+). Each signal is graded against sector-aware thresholds rather than one absolute bar, so MKSI is measured against Scientific & Technical Instruments peers, not against the market as a whole.
Is MKSI overvalued or undervalued?
Based on $264.50, MKSI sits about 228% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 45% next year, slowing to 4% a year by year ten. It trades at a 41.4x P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in MKSI?
Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.02 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.